Abstract Here, we describe a molecular switch associated with opioid receptors-linked signalling cascades that provides a dual opioid control over P2X 3 purinoceptor in sensory neurones. Leu-enkephalin inhibited P2X 3 -mediated currents with IC 50~1 0 nM in~25 % of small nociceptive rat dorsal root ganglion (DRG) neurones. In contrast, in neurones pretreated with pertussis toxin leu-enkephalin produced stable and significant increase of P2X 3 currents. All effects of opioid were abolished by selective μ-opioid receptor antagonist DPhe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), nonselective inhibitor naloxone, and by PLC inhibitor U73122. Thus, we discovered a dual link between purinoceptors and μ-opioid receptors: the latter exert both inhibitory (pertussis toxin-sensitive) and stimulatory (pertussis toxin-insensitive) actions on P2X 3 receptors through phospholipase C (PLC)-dependent pathways. This dual opioid control of P2X 3 receptors may provide a molecular explanation for dichotomy of opioid therapy. Pharmacological control of this newly identified facilitation/inhibition switch may open new perspectives for the adequate medical use of opioids, the most powerful pain-killing agents known today.
Introduction
Neurones located in the dorsal root ganglia (DRG) are principal cells involved in transmitting information of various somatosensory modalities. Small-and medium-sized neurones localized in the DRGs initiate the sensation of pain and hence are classified as nociceptive neurones [1] .
Numerous studies have indicated that homomeric P2X 3 ATP receptors expressed in the membrane of sensory neurones contribute to various types of pain behaviour, as well as pathological forms of nociception represented by hyperalgesia and allodynia [2] [3] [4] .
Opioids are commonly employed for pharmacological control of pain [5] , although their therapeutic usage is limited by multiple adverse effects and societal issues. It is generally acknowledged that opioids induce analgesia through their action on the central nervous system [6] . This perception, however, has been challenged with accumulation of evidence indicating that a considerable part of opioid analgesia is mediated by peripheral μ-, κ-and δ-opioid receptors [7] [8] [9] . Numerous clinical studies demonstrated that conventional and peripherally restricted opioid receptor agonists exhibit similar analgesic potency [10, 8] . The μ-opioid receptors (MORs) that belong to 7-transmembrane domain G protein-coupled receptors (GPCRs) coupled with pertussis toxin (PTX)-sensitive G i /G o proteins are predominantly expressed in small (nociceptive) DRG neurones [1] . Activation of MORs inhibits adenylate cyclase (AC) by the G α subunit, whereas G βγ subunits activate phospholipase C (PLC) with consequent production of second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (InsP 3 ) [11, 12] . Opioid-induced inhibition of AC-and cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) activity in sensory neurones reduces currents mediated by transient receptor potential vanilloid 1 (TRPV1) channels [13, 14] . Furthermore, opioids acting through MORs suppress voltage-gated Ca 2+ channels and stimulate G protein-mediated gating of inward-rectifier K + channels [15] [16] [17] [18] . Inhibition of MORs by naloxone was also reported to remove the antinociceptive action of P2X3 receptors antagonist A-317491 in rat models of chemogenic and inflammatory pain [19] . All these pathways represent peripheral sites of opioid analgesia, which curtails nociceptive signalling [20, 21] .
In the course of chronic treatment, analgesic effects of opioids are reduced (opioid tolerance) or even reversed resulting in hyperalgesia [22] [23] [24] . At the cellular level, opioid-induced hyperalgesia has been considered as a transition from classical PTX-sensitive inhibition of AC to PTX-insensitive stimulation of AC with consequent increase in the intracellular level of cAMP [25, 26] .
In the present study, we show that homomeric P2X 3 receptors are regulated by opioid signalling in a subpopulation of sensory neurones. Furthermore, we demonstrate a novel molecular mechanism for dual action of opioids on purinoceptors by presenting the data that stimulation of MORs exerts PTXsensitive inhibitory and PTX-insensitive stimulatory effects on P2X 3 receptors.
Materials and methods

Cell culture
Lumbar dorsal root ganglia (DRG; L1 to L5) were removed following decapitation of 8-day-old Wistar rats. After isolation, ganglia were treated with trypsine (1/250-2 mg/ml) and collagenase (type IV, 1 mg/ml) at 32°C for 35-40 min. Throughout the entire procedure, the medium (MEM) was continuously saturated with 95%O 2 +5 % CO 2 gas mixture (pH 7.4). Neurones dissociated by trituration were plated on glass coverslips and incubated in MEM medium supplemented with 10 % foetal bovine serum at 37°C. The cells were used for electrophysiological experiments after 2-3 days in vitro.
Electrophysiology
Whole-cell patch-clamp recordings were performed at room temperature (22 ± 1°C) using a patch-clamp amplifier (Axopatch 200B; Axon Instruments, Union City, CA, USA). Signals were filtered at 2 kHz with the in-built filter, digitized at 5 kHz and stored in a laboratory computer using Digidata 1200B interface and pCLAMP 8.0 software (Molecular Devices, California, USA). All recordings were made at a holding potential of −100 mV. The extracellular solution contained (in mM) 130 NaCl, 2 CaCl 2 , 5 KCl, 10 glucose and 10 HEPES (pH was adjusted to 7.4). The patch pipette solution (artificial intracellular medium) contained (in mM) 130 KCl, 10 HEPES, 10 EGTA, 0.5 GTP and 5 Mg-ATP (pH was adjusted to 7.3). The resistance of the pipettes was 5-7 MOhm.
Agonists of P2X 3 receptors were applied for 500 ms by a rapid U-tube system [27] positioned at a distance between 100 and 150 μm from the cell. The time of solution exchange was approximately 20-30 ms as confirmed by liquid junction potential measurements. The time needed for subsequent washout of applied saline was 100-150 ms (a more distantly located second U-tube was used for this purpose). The P2X-receptor agonist α,β-methylene-ATP (meATP), lithium salt was dissolved in external solution immediately before the experiments. The endogenous opioid peptide neurotransmitter leu-enkephalin (Enk) and the selective μ-opioid receptor agonist endomorphin-1 were used as opioid receptor agonists. All chemicals were obtained from Sigma (Grand Island, USA). ] i ) in isolated DRG neurones were imaged using the high-affinity fluorescent Ca 2+ indicator fluo-4, as previously described [28] . Briefly, the dye was loaded by 1-h incubation of the DRG neurones with 3 μM fluo-4 acetoxymethyl ester (fluo-4 AM; diluted from a stock containing 2 mM fluo-3 AM and 0.025 % (w/v) pluronic F-127 in dimethyl sulphoxide) followed by a 1-h wash in Ringer's solution to allow time for de-esterification. The cells were imaged using a LSM 5 PASCAL laser scanning confocal microscope (Carl Zeiss, Jena, Germany). The x-y confocal images were acquired at 0.5-2 Hz using a Zeiss Plan-Apochromat 40× 1.3 NA oilimmersion objective. The excitation beam was produced by the 488-nm line of a 200-mW argon ion laser, and illumination intensity was attenuated to 0.5-0.8 %. Fluo-4 fluorescence was captured at wavelengths above 505 nm. To optimize signal quality, the pinhole was set to provide a confocal optical section below 2 μm (measured with 0.2-μm fluorescent beads). The focus was adjusted to acquire the images from the middle of the cell depth. In the figures, the intensity of fluo-4 fluorescence was normalized to the average fluorescence intensity in the images captured before agonist application (F/F 0 ). The temporal profiles of the agonist-induced [Ca 2+ ] i transients are illustrated by the plots showing the normalized fluo-4 fluorescence intensity (F/F 0 ) averaged within an entire confocal optical slice of the cell.
Data analysis
Data are presented as mean±S.D. (where n is a number of tested opioid sensitive cells). The IC 50 is the concentration of a Enk that inhibited P2X 3 currents by 50 %. Commercially available software Origin 8.1 (OriginLab Corporation, USA) was used for data analysis. Statistical significance was evaluated using Student's t test. A probability value of P<0.05 was considered statistically significant (when necessary, marked by asterisks on the graphs).
Results
Leu-enkephalin inhibits P2X 3 receptors
Small (15-25 μm in diameter) DRG neurones were selected at the start of each experiment according to their responses to meATP [29] . Only neurones with fast and completely desensitizing (within 300-400 ms) ion currents characteristic for P2X 3 receptor were selected for subsequent study.
P2X 3 -mediated currents were evoked by 0.5 s applications of 30 μM meATP, which were delivered every 2-3 min. This concentration of meATP is close to saturating for the activation of P2X 3 receptors, whereas 2-to 3-min intervals between agonist applications ensure >90 % recovery of P2X 3 receptors from desensitization [30] . In all experiments, application of Enk was preceded by 2-3 applications of meATP performed to obtain a stable control current. Application of Enk resulted in two distinct outcomes: either it produced no effect (127 cells out of 171 individual neurones) or it inhibited P2X 3 -mediated currents ( Fig. 1; 44 neurones or 25.8 % of the selected cells). The inhibition was accelerated when the concentration of Enk was increased (Fig. 1b) , which indicates that kinetics of Enk binding to MORs rather than the rate of signal transduction is a limiting step for the inhibition of P2X 3 receptors. The inhibitory effect of Enk was dose-dependent and reversible (Fig. 1a, c) . Enk in the concentration of 1 nM did not produce any change in the P2X 3 current, but subsequent application of 1 μM Enk to the same cell resulted in complete current inhibition. After washout of Enk, the amplitude of P2X 3 -mediated current fully recovered within 6-8 min (Fig. 1) . Of note, application of 1 μM Enk completely (by 0.99±0.01, n=4) inhibited P2X 3 receptor-mediated currents in all opioid-sensitive neurones. Similarly, selective μ-opioid receptor agonist endomorphin-1 at 100 nM almost completely inhibited P2X 3 currents (by 0.97±0.02, n=3, data not shown).
Slow recovery from desensitization is a unique property of P2X 3 receptors. Its rate depends on the agonist (with recovery being the slowest when ATP is used for activation [30] ) and the temperature [31] ; the recovery from desensitization is inhibited by purotoxin-1 from spider venom [32] . To reveal possible effects of Enk on P2X 3 receptors recovery from desensitization, the meATP application protocol was modified. Initially, the cells were stimulated every 3 min by meATP before and during application of Enk (100 nM). When Enk reached its steady-state inhibition (about 65 %), the interval between meATP applications was increased to 9 min. The amplitude of the Enk-inhibited current remained unchanged (Fig. 2a, b) . Therefore, we concluded that Enk-mediated inhibition of P2X 3 receptors is not associated with modulation of the recovery from desensitization.
Prolonged application of Enk (18 min as shown on Inhibition of P2X 3 receptors is mediated by μ-opioid receptors Naloxone is a competitive opioid antagonist, which prevents opioid-receptor interaction thus blocking opioid signalling. Naloxone alone (50 nM to 1 μM) did not produce any changes in P2X 3 receptor-mediated currents (in cells incubated with 1 μM naloxone for 8 min, the average amplitude of P2X 3 current was 0.99±0.03, n=3 of the control value). Exposure to naloxone, however, removed Enk-dependent inhibition almost completely within 6-8 min (I/I contr =0.95±0.05, n=3; Fig. 2c, d ). The D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), the most selective antagonist of MOR [33] applied at 50 nM completely abolished inhibitory effect of 100 nM Enk (I/I contr =0.97±0.07, n=3, Fig. 2d ). Similarly to naloxone, exposure of DRG neurones to stop alone did not change the amplitude of P2X 3 currents (the average amplitude of P2X 3 current was 0.97±0.02, n=3 of the control value in cells exposed to 1 μM CTOP for 8 min).
High doses of opioid antagonists transiently augment P2X 3 receptor currents Exposure to 1 μM of naloxone not only removed MORmediated inhibition of P2X 3 current but also the amplitude of the P2X 3 current (in the presence of 100 nM Enk) exhibited an almost twofold and transient increase (I/I contr =2.1±0.3, n= 4). A similar transient increase was obtained following application of a high dose (1 μM) of СTOP: the I/I contr was 2.7±0.2 (n=4) (Fig. 3) .
This transient increase in the amplitude of P2X 3 current hinted for possible stimulatory effect of opioids (by analogy with the data on nodose neurones [34] ). In DRG neurones, pre-incubated with PTX (300 ng/ml) for 17-24 h application of Enk (10 nM-1 μM) resulted exclusively in facilitating effect on the P2X 3 current amplitude in all opioid-sensitive cells tested (n=11; Fig. 4a ). This facilitatory effect was completely removed by an application of naloxone (n=3, Fig. 4a, lower panel) .
When DRG neurones were exposed to naloxone (1 μM) for 2-4 min and subsequently naloxone solution was substituted by Enk, a substantial increase in the efficacy of the opioid inhibition of P2X 3 receptors was observed. In control settings, 1 nM Enk had no effect, whereas after preincubation with naloxone, the same concentration of Enk produced~50 % inhibition of P2X 3 currents within 10-12 min (Fig. 4b, upper panel) . Similarly, while 10 nM Enk inhibited P2X 3 currents by~50 % in control conditions (cf. Fig. 1 ) after pre-incubation with naloxone, the same concentration of Enk led to a complete block of the P2X 3 currents within 2 min (Fig. 4b, lower panel) . In summary, pre-incubation with naloxone decreases IC 50 for the inhibitory action of Enk from 10 to 1 nM (Fig. 4c) . Exposure of DRG neurones to PLC inhibitor U73122 at 1 μM concentration for 6-8 min did not affect P2X 3 currents (n=4; in the presence of the drug, the average amplitude of P2X 3 current was 0.98±0.04 of the control value). However, when U73122 was applied to the cells in which P2X 3 currents were completely blocked by a high dose of Enk, the current was restored to 0.87±0.11 (n=4) of the control (Fig. 5a) .
In DRG neurones pretreated with PTX for 17-24 h, both U73122 and PKC inhibitor staurosporine suppressed Enkinduced potentiation of P2X 3 -mediated currents (Fig. 5b) . Exposure of PTX-treated cells to Enk increased the peak amplitude of P2X 3 currents (I/I contr =1.56±0.2, n=7,* P<0.05); this stimulation was reduced to a control level by staurosporine (I/ I contr =1.04±0.1, n=3, P<0.05) and by U73122 (0.84±0.15, n=4). At the same time (and similarly to PTX-untreated cells), application of U73122 and staurosporine alone for 6-8 min did not affect P2X 3 currents (n=5). (Fig. 6a) . Treatment of these neurones with PTX for 17-24 h prior to the experiment substantially reduced but did not abolish Ca 2+ responses stimulated by Enk (Fig. 6b) , indicating that a subpopulation of PTX-insensitive G proteins link MORs to PLC; the Ca 2+ responses were observed in all six neurones studied.
Discussion
Dual effect of opioids on P2X 3 receptors
In this study, we demonstrate that activation of MORs exerts a dual (inhibitory and stimulatory) effect on P2X 3 currents in DRG neurones. In naïve cells, the application of opioid (Fig. 1) . In contrast, when opioids were presented to the cells pretreated with PTX, P2X 3 current amplitude was markedly increased (Figs. 4 and 5b) . We can therefore suggest that MORs signalling directed at P2X 3 receptors is mediated by both PTX-sensitive and PTXinsensitive G proteins that mediate opposite effects. In normal conditions, the inhibitory effect prevails, while stimulatory is either hidden or absent. The functional expression of PTXinsensitive metabotropic pathway was also confirmed by [Ca 2+ ] i recordings: a portion of ER-originating Ca 2+ release in response to Enk was preserved in PTX-treated neurones (Fig. 6) .
Biochemical studies indicate that MORs, like many other GPCRs, are capable of adopting several distinct active conformations coupled to different G proteins [35] . This feature of MORs-mediated signalling underlies for example dual influences on AC [36] . We may therefore assume that the dual action of MORs on P2X 3 receptors is similarly mediated by different MOR conformation states distinctly coupled to PTXsensitive/insensitive G proteins. Thus, opioid-induced stimulation/inhibition of P2X 3 receptors is associated with distinct intracellular pathways linked to different G proteins.
Both inhibitory and stimulatory effects of MORs on P2X 3 receptors are mediated by the PLC Membrane proteins and ion channels (including P2X 3 receptor) are regulated by a minor lipid constituent of plasma membrane, the phosphatidylinositol 4,5-bisphosphate or PIP 2 . Depletion of the membrane pool of PIP 2 leads to the inhibition of the P2X 3 current, which can be restored by addition of PIP 2 into the cytosol [37] ; activation of MOR leads to PLC- Exposure of PTX-treated cells to Enk increased the peak amplitude of P2X 3 currents, which action was antagonized by staurosporine and U73122. *P<0.05, statistically significant difference (n=5) mediated hydrolyses of PIP 2 thus depleting the membrane pool of the latter. Therefore, opioid-induced PIP 2 hydrolysis is likely to be responsible for the inhibition of P2X 3 currents. The role for PLC is further corroborated by the observation that the specific blocker, U73122, completely abolished opioid-induced inhibition of P2X 3 receptors (Fig. 5a ). Suppression of inhibitory component of dual opioid action on P2X 3 receptors could unmask normally hidden stimulatory component. However, in all the cells tested (n=4), U73122 restored the current inhibited by opioid back to the control level. This observation prompted a possibility that both opioid-induced stimulation and inhibition of P2X This, seemingly paradoxical, conclusion is in agreement with data on the regulation of P2X 3 receptors by other metabotropic pathways. For example, activation of P2Y 2 receptors inhibits P2X 3 via PTX-sensitive G i /G o linked to PLC, whereas bradykinin and substance P receptors coupled to PTX-insensitive G q proteins stimulate P2X 3 currents through PLC/PIP 2 /DAG/PKC cascade [38] [39] [40] . Assuming that similar pathways are used by MORs, one could expect that PKC is involved in the stimulatory action of MORs on P3X 3 receptors as well.
PKC is involved in the stimulatory action of MORs on P2X 3 receptors
Activation of PLC/PIP 2 pathway results in the generation of two second messengers, InsP 3 and DAG, with the phosphokinase C (PKC) being the ubiquitous target for the latter. Regulation of P2X 3 receptors by PKC is well documented [41] . We found that inhibition of PKC by staurosporine completely abolished opioid-induced stimulation of P2X 3 currents in DRG neurones treated with PTX (Fig. 5b) . The PKC can be activated either by DAG or by an increase in cytoplasmic Ca 2+ . Since concentration of the latter was clamped in our experimental conditions, it is likely that PLC/PIP 2 /DAG/PKC pathway is involved in the stimulation of P2X 3 receptors by MORs. That is, opioid-induced activation of PLC mediates not only inhibition but also stimulation of P2X 3 receptors.
The paradox of divergent PIP 2 signalling in the same membrane areas has been discussed in the past. It was proposed that molecular components of G protein/PLC signalling pathways and their final targets can be segregated between spatially separated microdomains [42] , while distinct pools of PIP 2 in plasma membrane have been identified by electron microscopy [43] . Depletion of the PIP 2 pool associated with P2X 3 receptors leads to the inhibition of P2X 3 current [37] . We suggest that hydrolysis of another PIP 2 indicating intracellular release) was attenuated to a much lesser degree pool separated from P2X 3 receptors induces their stimulation via the DAG/PKC pathway (Fig. 7) . Involvement of PKC in the stimulatory effect of MORs on nociceptors (putative hyperalgesia) found in our in vitro study is in conceptual agreement with in vivo findings according to which opioid-induced PLC/PKC signalling contributes to hyperalgesic effects of opioids. For example, supraspinal analgesic effects of morphine are enhanced in PKC-null mice [44] . In another study, morphine applied in extremely low dose produced hyperalgesia in the hot plate test, which effect involved PLC/PKC signalling pathway [45] .
Conformation-dependent interaction of MORs with antagonists separates intracellular pathways regulating P2X 3 
receptors
We propose that in the subpopulation of DRG neurones, P2X 3 receptors are subjected to inhibitory and excitatory regulation mediated by diverse MOR conformation states coupled to different G proteins. In physiological conditions, an inhibition of P2X 3 receptors prevails and hence masks the effect of stimulatory arm. However, when MOR inhibitors (naloxone or CTOP) are applied at a high dose, the stimulation of P2X 3 receptors becomes transiently visible (as shown on Fig. 3 ). This may reflect the higher rate of interaction of antagonists with "inhibitory" MOR conformation. This phenomenon is in qualitative agreement with strong increase in efficiency of opioid inhibition after naloxone pretreatment (Fig. 4b) : MOR receptors tend to bind the antagonist when being in the "inhibitory" conformation. The latter dominates when the antagonist is replaced by the agonist. Incidentally, after naloxone is washed out, MORs maintain a persistent (exceeding several minutes) "memory" for the increased opioid efficiency (Fig. 4b) . A similar long-lasting MOR 'memory' has been described recently in other types of experiments: it was found that the affinity of MORs to an agonist is increased dramatically by prior agonist exposure [46] . These findings and results of our experiments indicate that interactions with agonists and antagonists can produce long-term changes in the conformation of MORs.
To summarize possible MOR/P2X 3 interactions (Fig. 7) , we propose that MORs can acquire distinct conformational states differentially coupled to PTX-sensitive (G i/o ) and PTX-insensitive (most probably G q ) G proteins. The conformational state coupled to G i/o proteins activates PLC, which in turn mediates hydrolysis of the PIP 2 pool associated with P2X 3 receptors. Depletion of this PIP 2 pool results in the inhibition of P2X 3 currents. In contrast, the alternative (possibly G q -mediated) pathway hydrolyses a separate pool of PIP 2 , which is not associated with P2X 3 receptors. We suggest that DAG which is synthesized during this hydrolysis may activate PKC that stimulates P2X 3 receptors. Indeed, inhibition of PKC with staurosporine eliminates stimulation of P2X 3 receptors. Naturally, we have to further suggest that DAG appears in both microdomains; however, inhibitory action of PIP 2 depletion prevails and thus overpowers the PKC-dependent stimulation. As a result, several modes of P2X 3 receptors coexist in opioids-sensitive sensory neurones: some receptors appear in the inhibited state, some in stimulated and some can be simultaneously inhibited and stimulated. Balancing of the inhibitory and stimulatory arms defines the receptor availability and nociceptive phenotype of the neurone; when under chronic opioids treatment or in response to opioid receptor antagonist therapy, the loss of this balance may contribute to pathological nociception. Fig. 7 Proposed bimodal signalling pathways activated by opioid and leading to inhibition and enhancement of P2X 3 receptor-mediated current in DRG neurones. Activated MORs may acquire two distinct states associated either with G proteins. Two distinct PIP 2 pools linked with P2X 3 receptor (upper panel) or separated from it (lower panel), are both hydrolyzed by PLC (that can be inhibited by U73122), which is activated either by G i/o (sensitive to PTX) or by (yet unidentified) PTXinsensitive G proteins. Hydrolysis of the PIP 2 pool associated with P2X 3 receptor results in the inhibition of the latter. Hydrolysis of PIP 2 pool separated from P2X 3 receptor results in the generation of second messenger DAG, which activates PKC (that can be inhibited by staurosporine); activated PKC in turn may stimulate P2X 3 receptors. Thus, P2X 3 receptor is subjected to the two opposite regulatory influences: inhibition via G i/o /PLC/PIP 2 pathway and stimulation through G q /PLC/PIP 2 /DAG/PKC pathway
In conclusion, activation of MORs normally inhibits P2X 3 responses in DRG neurones; when treated, however, with high doses of MOR antagonists, the stimulation of P2X 3 receptors can transiently occur. Although the functional significance of the stimulatory action of opioids needs further investigation, it is possible that corresponding G protein machinery may contribute to the pro-nociceptive effects of opioids occurring in pathological conditions such as opioid-induced hyperalgesia. Another adverse effect of opioids, namely antagonist-induced opioid hypersensitivity is similarly in concordance with the phenomena observed at a single cell level. Search for pharmacological control of the mechanisms operating inhibition/ excitation switch may be important for the future development of antinociceptive therapies.
